{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:59Z","timestamp":1793272799050,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2023-242"],"award-info":[{"award-number":["BJ-2023-242"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2022-118"],"award-info":[{"award-number":["BJ-2022-118"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2023-209"],"award-info":[{"award-number":["BJ-2023-209"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373272"],"award-info":[{"award-number":["82373272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Science","award":["2021-I2M-1-050"],"award-info":[{"award-number":["2021-I2M-1-050"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2021QH260"],"award-info":[{"award-number":["ZR2021QH260"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06867-8","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:15:15Z","timestamp":1753445715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reversing the \u201ccold\u201d tumor microenvironment: the role of neoantigen vaccines in prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Jiani","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-2987","authenticated-orcid":false,"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"6867_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"6867_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"6867_CR3","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.3390\/cancers15235615","volume":"15","author":"S Wasim","year":"2023","unstructured":"Wasim S, Park J, Nam S, Kim J. Review of current treatment intensification strategies for prostate cancer patients. Cancers. 2023;15:5615.","journal-title":"Cancers"},{"key":"6867_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00873-5","author":"JW Yaxley","year":"2024","unstructured":"Yaxley JW, Fitzgerald B. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis \u201cPCAN-23-0763R.\u201d Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00873-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6867_CR5","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.2147\/OTT.S117176","volume":"9","author":"AS Merseburger","year":"2016","unstructured":"Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263\u201374.","journal-title":"Onco Targets Ther"},{"key":"6867_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:697\u2013717.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6867_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","volume":"18","author":"YuJ Xin","year":"2019","unstructured":"Xin YuJ, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18:899\u2013900.","journal-title":"Nat Rev Drug Discov"},{"issue":"1972\u20131988","key":"6867_CR8","volume":"41","author":"JE Hawley","year":"2023","unstructured":"Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, McKiernan J, Anderson CB, Decastro GJ, Weintraub J, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell. 2023;41(1972\u20131988): e1975.","journal-title":"Cancer Cell"},{"key":"6867_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859785","volume":"13","author":"A Mulvey","year":"2022","unstructured":"Mulvey A, Muggeo-Bertin E, Berthold DR, Herrera FG. Overcoming immune resistance with radiation therapy in prostate cancer. Front Immunol. 2022;13: 859785.","journal-title":"Front Immunol"},{"key":"6867_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"6867_CR11","doi-asserted-by":"publisher","first-page":"18801","DOI":"10.1021\/acsnano.4c05065","volume":"18","author":"T Liu","year":"2024","unstructured":"Liu T, Yao W, Sun W, Yuan Y, Liu C, Liu X, Wang X, Jiang H. Components, formulations, deliveries, and combinations of tumor vaccines. ACS Nano. 2024;18:18801\u201333.","journal-title":"ACS Nano"},{"key":"6867_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"6867_CR13","doi-asserted-by":"publisher","first-page":"1745108","DOI":"10.1155\/2016\/1745108","volume":"2016","author":"K Takayama","year":"2016","unstructured":"Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, et al. Randomized Phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients with previously treated advanced wild type EGFR non-small-cell lung cancer. J Immunol Res. 2016;2016:1745108.","journal-title":"J Immunol Res"},{"key":"6867_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6:26.","journal-title":"Signal Transduct Target Ther"},{"key":"6867_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3892\/ijo.2012.1573","volume":"41","author":"T Masuzawa","year":"2012","unstructured":"Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, et al. Phase I\/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41:1297\u2013304.","journal-title":"Int J Oncol"},{"key":"6867_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","volume":"122","author":"DH Palmer","year":"2020","unstructured":"Palmer DH, Valle JW, Ma YT, Faluyi O, Neoptolemos JP, Jensen Gjertsen T, Iversen B, Amund Eriksen J, Moller AS, Aksnes AK, et al. TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial. Br J Cancer. 2020;122:971\u20137.","journal-title":"Br J Cancer"},{"key":"6867_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","volume":"592","author":"M Platten","year":"2021","unstructured":"Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463\u20138.","journal-title":"Nature"},{"key":"6867_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27:515\u201325.","journal-title":"Nat Med"},{"key":"6867_CR19","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753\u20138.","journal-title":"Clin Cancer Res"},{"key":"6867_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"6867_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.CIR-15-0134","volume":"3","author":"PK Srivastava","year":"2015","unstructured":"Srivastava PK. Neoepitopes of cancers: looking back, looking ahead. Cancer Immunol Res. 2015;3:969\u201377.","journal-title":"Cancer Immunol Res"},{"key":"6867_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000002181","volume":"135","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Jia Q, Zhang J, Zhu B. Neoantigens in precision cancer immunotherapy: from identification to clinical applications. Chin Med J (Engl). 2022;135:1285\u201398.","journal-title":"Chin Med J (Engl)"},{"key":"6867_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol. 2019;37:173\u2013200.","journal-title":"Annu Rev Immunol"},{"issue":"3201\u20133213","key":"6867_CR24","volume":"185","author":"L Susac","year":"2022","unstructured":"Susac L, Vuong MT, Thomas C, von Bulow S, O\u2019Brien-Ball C, Santos AM, Fernandes RA, Hummer G, Tampe R, Davis SJ. Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC. Cell. 2022;185(3201\u20133213): e3219.","journal-title":"Cell"},{"key":"6867_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","volume":"2","author":"EF Fritsch","year":"2014","unstructured":"Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014;2:522\u20139.","journal-title":"Cancer Immunol Res"},{"key":"6867_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 2017;9:34.","journal-title":"Genome Medicine"},{"key":"6867_CR27","doi-asserted-by":"publisher","first-page":"D436","DOI":"10.1093\/nar\/gkae1092","volume":"53","author":"R Vita","year":"2025","unstructured":"Vita R, Blazeska N, Marrama D, Duesing S, Bennett J, Greenbaum J, De Almeida MM, Mahita J, Wheeler DK, Cantrell JR, et al. The Immune Epitope Database (IEDB): 2024 update. Nucleic Acids Res. 2025;53:D436\u201343.","journal-title":"Nucleic Acids Res"},{"key":"6867_CR28","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC Class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360\u20138.","journal-title":"J Immunol"},{"key":"6867_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216192","volume":"563","author":"S-F Yang","year":"2023","unstructured":"Yang S-F, Weng M-T, Liang J-D, Chiou L-L, Hsu Y-C, Lee Y-T, Liu S-Y, Wu M-C, Chou H-C, Wang L-F, et al. Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Lett. 2023;563: 216192.","journal-title":"Cancer Lett"},{"key":"6867_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJM Melief","year":"2008","unstructured":"Melief CJM, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351\u201360.","journal-title":"Nat Rev Cancer"},{"key":"6867_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2023","unstructured":"Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2023;24:213\u201327.","journal-title":"Nat Rev Immunol"},{"key":"6867_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131:49\u201357.","journal-title":"Blood"},{"key":"6867_CR33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cancers13102288","volume":"13","author":"K Hashimoto","year":"2021","unstructured":"Hashimoto K. CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development. Cancers. 2021;13:2288.","journal-title":"Cancers"},{"key":"6867_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-62658-7_2","volume":"1302","author":"N Reyes","year":"2021","unstructured":"Reyes N, Figueroa S, Tiwari R, Geliebter J. CXCL3 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1302:15\u201324.","journal-title":"Adv Exp Med Biol"},{"key":"6867_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2022.114884","volume":"220","author":"Q Ruan","year":"2023","unstructured":"Ruan Q, Lin X, Wang L, Wang N, Zhao Y, Wang H, Tian F-Y, Hu N, Li Y, Zhao B. An engineered (CAGA)12-EGFP cell-based biosensor for high-content and accurate detection of active TGF-\u03b2. Biosens Bioelectron. 2023;220: 114884.","journal-title":"Biosens Bioelectron"},{"key":"6867_CR36","first-page":"339","volume":"14","author":"F Turco","year":"2022","unstructured":"Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Res Rep Urol. 2022;14:339\u201350.","journal-title":"Res Rep Urol"},{"key":"6867_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, Reading JL, Joshi K, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385.","journal-title":"Nature"},{"key":"6867_CR38","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4049\/jimmunol.2100700","volume":"208","author":"ES Borden","year":"2022","unstructured":"Borden ES, Ghafoor S, Buetow KH, LaFleur BJ, Wilson MA, Hastings KT. NeoScore integrates characteristics of the neoantigen:MHC Class I interaction and expression to accurately prioritize immunogenic neoantigens. J Immunol. 2022;208:1813\u201327.","journal-title":"J Immunol"},{"key":"6867_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8:9.","journal-title":"Signal Transduct Target Ther"},{"key":"6867_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001111","volume":"8","author":"MY Lee","year":"2020","unstructured":"Lee MY, Jeon JW, Sievers C, Allen CT. Antigen processing and presentation in cancer immunotherapy. J Immunother Cancer. 2020;8: e001111.","journal-title":"J Immunother Cancer"},{"key":"6867_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"6867_CR42","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1158\/1078-0432.CCR-19-0596","volume":"25","author":"AM Jaeger","year":"2019","unstructured":"Jaeger AM, Stopfer L, Lee S, Gaglia G, Sandel D, Santagata S, Lin NU, Trepel JB, White F, Jacks T, et al. Rebalancing protein homeostasis enhances tumor antigen presentation. Clin Cancer Res. 2019;25:6392\u2013405.","journal-title":"Clin Cancer Res"},{"key":"6867_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696\u2013701.","journal-title":"Nature"},{"key":"6867_CR44","doi-asserted-by":"publisher","first-page":"D428","DOI":"10.1093\/nar\/gkac965","volume":"51","author":"DM Tadros","year":"2023","unstructured":"Tadros DM, Eggenschwiler S, Racle J, Gfeller D. The MHC Motif Atlas: a database of MHC binding specificities and ligands. Nucleic Acids Res. 2023;51:D428\u201337.","journal-title":"Nucleic Acids Res"},{"key":"6867_CR45","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.immuni.2023.03.009","volume":"56","author":"J Racle","year":"2023","unstructured":"Racle J, Guillaume P, Schmidt J, Michaux J, Larabi A, Lau K, Perez MAS, Croce G, Genolet R, Coukos G, et al. Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity. 2023;56:1359-1375.e1313.","journal-title":"Immunity"},{"key":"6867_CR46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, et al. Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial. JAMA Oncol. 2022;8:546\u201352.","journal-title":"JAMA Oncol"},{"key":"6867_CR47","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051\u201361.","journal-title":"J Clin Oncol"},{"key":"6867_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139.","journal-title":"Science"},{"key":"6867_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-022-04839-2","volume":"607","author":"AM Jaeger","year":"2022","unstructured":"Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM 3rd, Naranjo S, Fessenden T, Nguyen KB, et al. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022;607:149\u201355.","journal-title":"Nature"},{"key":"6867_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380.","journal-title":"Science"},{"key":"6867_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22:158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"6867_CR52","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3390\/cancers15051495","volume":"15","author":"HG Nair","year":"2023","unstructured":"Nair HG, Jurkiewicz A, Graczyk D. Inhibition of RNA polymerase III augments the anti-cancer properties of TNFalpha. Cancers. 2023;15:1495.","journal-title":"Cancers"},{"key":"6867_CR53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"6867_CR54","doi-asserted-by":"publisher","first-page":"1181051","DOI":"10.3389\/fimmu.2023.1181051","volume":"14","author":"M Noori","year":"2023","unstructured":"Noori M, Azizi S, Mahjoubfar A, Abbasi Varaki F, Fayyaz F, Mousavian AH, Bashash D, Kardoust Parizi M, Kasaeian A. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1181051.","journal-title":"Front Immunol"},{"key":"6867_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"6867_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923\u201337.","journal-title":"Cancer Cell"},{"key":"6867_CR57","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","volume":"74","author":"J Fourcade","year":"2014","unstructured":"Fourcade J, Sun Z, Pagliano O, Chauvin J-M, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8\u207a T cells induced by melanoma vaccines. Can Res. 2014;74:1045\u201355.","journal-title":"Can Res"},{"key":"6867_CR58","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081\u201391.","journal-title":"Cancer Res"},{"key":"6867_CR59","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s00432-021-03735-y","volume":"147","author":"J Sun","year":"2021","unstructured":"Sun J, Zhang J, Hu H, Qin H, Liao X, Wang F, Zhang W, Yin Q, Su X, He Y, et al. Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer. J Cancer Res Clin Oncol. 2021;147:3255\u201368.","journal-title":"J Cancer Res Clin Oncol"},{"key":"6867_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/jnci\/93.13.998","volume":"93","author":"TS Griffith","year":"2001","unstructured":"Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst. 2001;93:998\u20131007.","journal-title":"J Natl Cancer Inst"},{"issue":"12_Supplement","key":"6867_CR61","first-page":"1664","volume":"82","author":"S Justin","year":"2002","unstructured":"Justin S, Derrik G, Patrick A, Alden W, Sylvie K. Abstract 1664: Model characterization and tumor immune profile assessment for syngeneic RM-1 murine prostate cancer in male C57BL\/6 mice. Cancer Res. 2002;82(12_Supplement):1664.","journal-title":"Cancer Res"},{"key":"6867_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euros.2023.08.001","volume":"55","author":"HY Hougen","year":"2023","unstructured":"Hougen HY, Graf RP, Li G, Quintanilha JCF, Lin DI, Ross JS, Punnen S, Mahal BA. Clinical and genomic factors associated with greater tumor mutational burden in prostate cancer. Eur Urol Open Sci. 2023;55:45\u20139.","journal-title":"Eur Urol Open Sci"},{"key":"6867_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106709","volume":"86","author":"C Luo","year":"2020","unstructured":"Luo C, Chen J, Chen L. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Int Immunopharmacol. 2020;86: 106709.","journal-title":"Int Immunopharmacol"},{"key":"6867_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12894-021-00795-7","volume":"21","author":"L Wang","year":"2021","unstructured":"Wang L, Pan S, Zhu B, Yu Z, Wang W. Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urol. 2021;21:29.","journal-title":"BMC Urol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:45:48Z","timestamp":1757288748000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6867"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06867-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal research was performed in accordance with the Basel Declaration and approved by the Ethics Committee of Institute of Zoology Chinese Academy of Sciences (IOZ-IACUC-2023-270).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"835"}}